AR069420A1 - Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo - Google Patents

Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo

Info

Publication number
AR069420A1
AR069420A1 ARP080105093A ARP080105093A AR069420A1 AR 069420 A1 AR069420 A1 AR 069420A1 AR P080105093 A ARP080105093 A AR P080105093A AR P080105093 A ARP080105093 A AR P080105093A AR 069420 A1 AR069420 A1 AR 069420A1
Authority
AR
Argentina
Prior art keywords
diarrhea
somatostatin
plga
lactic
treatment
Prior art date
Application number
ARP080105093A
Other languages
English (en)
Inventor
Garces Josep Garces
Vizcaino Ricard Mis
Claudio Savulsky
Duena Antonio Parente
Original Assignee
Gp Pharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp Pharm Sa filed Critical Gp Pharm Sa
Publication of AR069420A1 publication Critical patent/AR069420A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composicion farmacéutica de somatostatina, o un análogo de somatostatina, de liberacion sostenida para su uso en el tratamiento y/o prevencion de la diarrea y su uso en la preparacion de un medicamento para el tratamiento y/o prevencion de la diarrea. Reivindicacion 1: Composicion de microcápsulas de copolímero láctico-co-glicolico (PLGA) o copolímero láctico-co-glicolico y polietilenglicol (PLGA-PEG) comprendiendo somatostatina, o un análogo de somatostatina, para uso en el tratamiento y/o prevencion de la diarrea, caracterizado porque las microcápsulas de PLGA o PLGA-PEG liberan sostenidamente una cantidad terapéuticamente eficaz de somatostatina, o un análogo de somatostatina, durante un período de entre 3 y 10 días desde su administracion. Reivindicacion 2: Composicion de microcápsulas de copolímero láctico-co-glicolico (PLGA) o copolímero láctico-co-glicolico y polietilenglicol (PLGA-PEG) comprendiendo somatostatina, o un análogo de somatostatina, para uso en el tratamiento y/o prevencion de la diarrea segun la reivindicacion 1, donde la diarrea se selecciona del grupo formado por diarrea asociada a la quimioterapia o asociada a la radioterapia abdominal y/o pélvica en el tratamiento del cáncer, diarrea como uno de los síntomas del SIDA, diarrea asociada a la enfermedad del injerto contra el huésped gastrointestinal aguda, diarrea asociada a colitis ulcerosa, colitis colagenosa, colitis microscopica, colitis linfocítica, enfermedad de Crohn, diarreas de origen infeccioso vírico y diarreas de origen bacteriano. Reivindicacion 11: Composicion de microcápsulas de copolímero láctico-co-glicolico (PLGA) o copolímero láctico-co-glicolico y polietilenglicol (PLGA-PEG) comprendiendo somatostatina, o un análogo de somatostatina, para uso en el tratamiento y/o prevencion de la diarrea segun la reivindicacion 10, donde la somatostatina, o un análogo de somatostatina, se selecciona del grupo formado por acetato de octreotide, acetato de somatostatina o acetato de lanreotida.
ARP080105093A 2007-11-23 2008-11-24 Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo AR069420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200703103A ES2324009B1 (es) 2007-11-23 2007-11-23 Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.

Publications (1)

Publication Number Publication Date
AR069420A1 true AR069420A1 (es) 2010-01-20

Family

ID=40589822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105093A AR069420A1 (es) 2007-11-23 2008-11-24 Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo

Country Status (13)

Country Link
US (1) US20110124563A1 (es)
EP (1) EP2223684B1 (es)
AR (1) AR069420A1 (es)
CL (1) CL2008003489A1 (es)
CY (1) CY1114045T1 (es)
DK (1) DK2223684T3 (es)
ES (2) ES2324009B1 (es)
HR (1) HRP20130447T1 (es)
PL (1) PL2223684T3 (es)
PT (1) PT2223684E (es)
SI (1) SI2223684T1 (es)
TW (1) TWI463991B (es)
WO (1) WO2009068708A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180054627A (ko) 2015-09-21 2018-05-24 테바 파마슈티컬스 인터내셔널 게엠베하 서방형 올란자핀 제제
US10980882B2 (en) * 2015-09-25 2021-04-20 Jennifer J. KANG-MIELER Biodegradable microsphere-hydrogel ocular drug delivery system
US11266608B2 (en) 2015-09-25 2022-03-08 Jennifer J. Kang-Mteler Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
TWI795423B (zh) 2017-07-17 2023-03-11 法商麥迪榭爾公司 用於調節至少一種活性成份之藥物釋放動力學的可生物降解之藥物傳遞之組合物混合物
FR3079421A1 (fr) * 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
AU2022390573A1 (en) * 2021-11-22 2024-05-16 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
SE9100610D0 (sv) * 1991-03-04 1991-03-04 Procordia Ortech Ab Bioresorbable material for medical use
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
DE19621533A1 (de) * 1996-05-29 1997-12-04 Bosch Gmbh Robert Elektromotorische Bremsvorrichtung
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
US8871269B2 (en) * 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
BRPI0620063B8 (pt) * 2005-12-22 2021-05-25 Novartis Ag composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração

Also Published As

Publication number Publication date
PT2223684E (pt) 2013-06-20
WO2009068708A2 (es) 2009-06-04
CY1114045T1 (el) 2016-07-27
ES2414472T3 (es) 2013-07-19
EP2223684A2 (en) 2010-09-01
SI2223684T1 (sl) 2013-07-31
ES2324009B1 (es) 2010-05-21
WO2009068708A8 (es) 2010-10-21
PL2223684T3 (pl) 2013-08-30
DK2223684T3 (da) 2013-06-17
WO2009068708A3 (es) 2009-07-16
US20110124563A1 (en) 2011-05-26
TW200936157A (en) 2009-09-01
HRP20130447T1 (en) 2013-06-30
CL2008003489A1 (es) 2009-05-29
TWI463991B (zh) 2014-12-11
EP2223684B1 (en) 2013-03-27
ES2324009A1 (es) 2009-07-28

Similar Documents

Publication Publication Date Title
AR069420A1 (es) Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo
CO2017007003A2 (es) Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares
ES2531215T3 (es) Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
MX344831B (es) Composiciones para el transplante floral fecal y metodos para elaborar y utilzar las mismas y dispositivos para suministrar las mismas.
AR065246A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos
AR061620A1 (es) Suspensiones acuosas de tmc278
HRP20110800T1 (hr) UPORABA 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOKSO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILA ZA LIJEČENJE DIJABETESA, RAKA, AUTOIMUNIH POREMEĆAJA I ZARAZE HIV-om
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
AR112480A1 (es) Composiciones de glp-1 y sus usos
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
MX363023B (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos.
JP2011225596A5 (es)
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
JP2010222367A5 (es)
CR11724A (es) Agente para tratar enfermedades
PE20060507A1 (es) Composicion farmaceutica que contiene acido micofenolico con recubrimiento de liberacion modificada
PE20121495A1 (es) Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
CO6190623A2 (es) Vacuna salmonella
HRP20191723T1 (hr) Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
JP2009500045A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure